Evidence map›Paper›PMID 29671808›Full record

ReviewMolecules (Basel, Switzerland)2018

HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data.

Olga Tarasova, Vladimir Poroikov

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olga TarasovaInstitute of Biomedical Chemistry, 10 building 8, Pogodinskaya st., Moscow 119121, Russia. olga.a.tarasova@gmail.com.ORCID 0000-0002-3723-7832
Vladimir PoroikovInstitute of Biomedical Chemistry, 10 building 8, Pogodinskaya st., Moscow 119121, Russia. vladimir.poroikov@ibmc.msk.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research and development of new antiretroviral agents are in great demand due to issues with safety and efficacy of the antiretroviral drugs. HIV reverse transcriptase (RT) is an important target for HIV treatment. RT inhibitors targeting early stages of the virus-host interaction are of great interest for researchers. There are a lot of clinical and biochemical data on relationships between the occurring of the single point mutations and their combinations in the pol gene of HIV and resistance of the particular variants of HIV to nucleoside and non-nucleoside reverse transcriptase inhibitors. The experimental data stored in the databases of HIV sequences can be used for development of methods that are able to predict HIV resistance based on amino acid or nucleotide sequences. The data on HIV sequences resistance can be further used for (1) development of new antiretroviral agents with high potential for HIV inhibition and elimination and (2) optimization of antiretroviral therapy. In our communication, we focus on the data on the RT sequences and HIV resistance, which are available on the Internet. The experimental methods, which are applied to produce the data on

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV Reverse TranscriptaseHumansReverse Transcriptase InhibitorsAnti-HIV AgentsHIV Reverse TranscriptaseReverse Transcriptase Inhibitorsamino acid sequencescomputational predictionHIVnucleotide sequencesopen dataresistancereverse transcriptase

Identifiers

PMID29671808
PMCPMC6017644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.